Top HealthTech Companies in Europe (2026)
Europe’s healthtech ecosystem is no longer just “emerging.” In 2026, it is structurally reshaping how healthcare is delivered, financed, and optimized; from AI diagnostics to consumer wearables and digital-first care platforms.
This overview goes beyond a simple ranking, highlighting the top healthtech companies in Europe in 2026.
Instead, it maps the three forces defining European healthtech today:
Valuation
leaders
Scaled platforms and unicorns
Strategic
innovators
AI, data, and infrastructure players
High-growth disruptors
New models redefining care delivery
Last updated: March 2026
How This Ranking Works
There is no single “top healthtech companies” list.
Companies included in this overview:
- Operate independently in 2026
- Show meaningful scale (valuation, revenue, or adoption)
- Are recognized leaders in their category
Valuations are based on the latest available funding data or public market signals.
Public → market cap (fluctuates)
[Unverified] → estimated from last known round
Snapshot: Europe’s Leading HealthTech Companies (2026)
| Company | Country | Segment | Category | Est. Valuation |
|---|---|---|---|---|
| Doctolib | France | Care platform | Leader | €5–6B [Unverified] |
| Alan | France | Digital insurance | Leader | ~$4B [Unverified] |
| Oura | Finland | Wearables | Leader | $2.5–3B [Unverified] |
| Kry | Sweden | Telehealth | Leader | $1–2B [Unverified] |
| Flo Health | UK | Femtech | Leader | $0.8–1B [Unverified] |
| Owkin | France | AI drug discovery | Innovator | ~$1B+ |
| Sophia Genetics | Switzerland | Genomics/data | Innovator | Public (~$0.2–0.5B) |
| Infermedica | Poland | AI triage | Innovator | Not disclosed |
| Sidekick Health | Iceland | Digital therapeutics | Innovator | $300–400M [Unverified] |
| Oviva | Switzerland | Digital therapeutics | Innovator | ~$500M+ [Unverified] |
| Neko Health | Sweden | Preventive diagnostics | Disruptor | ~$1B+ [Unverified] |
| Cera Care | UK | Home healthcare | Disruptor | ~$1B+ |
| Liva Healthcare | Denmark | Chronic care | Disruptor | Not disclosed |
Valuations are based on the latest publicly available funding data and market estimates.
Private company valuations may have changed since the last reported rounds.
Top HealthTech Companies in Europe by Category
Valuation Leaders: Europe’s HealthTech Heavyweights
Doctolib (France)
Estimated valuation: ~€6B [Unverified]
Doctolib remains Europe’s most dominant digital health platform, deeply integrated into provider workflows.
Why it leads?
- Strong network effects
- Embedded in care delivery
- Expanding into coordination and patient engagement
Alan (France)
Estimated valuation: ~$4B+
Alan combines insurance, prevention, and digital tools into a single platform.
Closer to a health super-app than a traditional payer.
Oura (Finland)
Estimated valuation: ~$2.5–3B [Unverified]
Oura represents the consumerization of healthtech, shifting focus toward continuous monitoring and prevention.
Kry / Livi (Sweden)
Estimated valuation: ~$2B+ [Unverified]
A major European telehealth player is navigating post-COVID normalization and tighter funding conditions.
Telehealth alone is no longer sufficient — integration is key.
Strategic Innovators: Building the Future Stack
Owkin (France)
One of Europe’s strongest AI-native companies.
Key strengths:
• Federated learning models
• Deep pharma partnerships
• Scalable AI infrastructure
Sophia Genetics (Switzerland)
A foundational layer for precision medicine in Europe.
Sidekick Health (Iceland)
Digital therapeutics platform for chronic disease.
High-Growth Disruptors: Redefining Healthcare Models
Neko Health (UK, Sweden)
A new model of proactive healthcare focused on full-body scanning and early detection.
Cera Care (UK)
Digitizing one of the largest, least efficient healthcare segments: home healthcare delivery.
Chronic care
Liva Healthcare (Denmark)
Digital platform for lifestyle and chronic disease management.
KEY TRENDS (2026)
What Is Shaping European HealthTech
- AI is becoming foundational
- Differentiation comes from clinical integration
- Consumer and clinical health are converging (Oura, Flo, Neko)
- Platforms outperform point solutions
- Regulation shapes competition (EU AI Act, MDR)
- Funding is more selective
- Focus on revenue and efficiency
EUROPE VS US
Structural Differences
Europe
- strong clinical integration
- slower scaling
- regulatory complexity
US
- more capital
- faster commercialization
- higher valuations
Conclusion:
Europe builds more system-integrated companies
FAQ
Doctolib and Alan are among the most valuable platform players.
Yes, including Doctolib, Alan, Oura, Owkin, and Cera Care.
Private company valuations are based on the latest funding rounds and may change over time.
What has Changed?
